Drug Profile
Insulin suspension isophane biosimilar - Wockhardt
Alternative Names: Recombinant (r-DNA) intermediate acting human insulin NPH /isophane - Wockhardt; Wosulin-NLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-III for Type 1 diabetes mellitus in USA (SC)
- 19 Jun 2020 Wockhardt plans a phase I bioavailability trial (In volunteers) in India (SC, Injection) (CTRI2020-06-026261)
- 21 Aug 2013 Wockhardt terminates a phase III trial in Type 1 diabetes mellitus in USA and India (NCT01308437)